Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06935864

Tissue Expression of Krüppel-Like Factors 4 and 7 in Bone Tumors

The current study is to assess the prognostic value of Krüppel-like factors 4 and 7 in bone tumors, and its role in the disease progression.

Recruiting

Interested in participating?

Request Info

Key information

Age range

1 month–39 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ain Shams University, Cairo, Egypt

Loading trial locations.

About this study

Krüppel-like factors are a group of proteins that engage in different cell functions including proliferation, apoptosis, autophagy, invasion, and migration, and have been discovered to play an important role in bone disease development.

Study Setting: Pediatric Hematology, Oncology and Bone Marrow Transplantation Unit at Ain Shams University Children's Hospital.

  • Type of Study: Prospective cohort.
  • Study Period: 12 months.
  • Study Population: Children, adolescents, and young adults diagnosed with localized and metastatic both skeletal and extra-skeletal osteosarcoma and Ewing's sarcoma
  • Sampling Method: Convenience
  • The medical history by direct interview of participants or from the patients files with a focus on:
  • Symptoms such as pain, swelling, and fracture including duration, intensity, and timing of complaint.
  • Specific events for bone tumors include prior benign/malignant lesions, family history, and previous radiotherapy for a prior cancer.
  • Assessment of the adverse outcomes.
  • Treatment protocol, timing of local control, type of local surgical control, need for adjuvant or definitive radiation therapy.
  • Examination carried out upon initial patients' presentation (collected from files in the historical group):
  • A full physical examination including weight and height, with calculation of body mass index (BMI) and surface area (SA).
  • Local examination with specific attention to the size, consistency of the swelling, its location and mobility, the relation of swelling to the involved bone, and the presence of regional/ local lymph nodes.
  • Radiologic investigations at initial diagnosis, after induction chemotherapy, after local control, as well as at the end of therapy and every 3 months during 1st 2 years after therapy (collected from files in the historical group):
  • Conventional radiographs in two planes
  • Magnetic resonance imaging (MRI) of the whole compartment with adjacent joints,
  • Computed tomography (CT) should be used only in the case of diagnostic problems or doubt, to visualize more clearly calcification, periosteal bone formation, or cortical destruction
  • Stage classification: positron emission tomography (PET)/CT using General Electric device number 5632.
  • Laboratory assessment at presentation for cohort group (collected from files in the historical group)
  • Complete blood count (CBC)
  • Electrolytes including serum Calcium, phosphorus, magnesium, bicarbonate; creatinine, blood urea nitrogen, liver enzymes, and lactate dehydrogenase (LDH)
  • Pathological methods:
  • Histopathological examination of H&E-stained sections prepared from paraffin blocks at 4-5 um thickness.
  • Immunohistochemical staining of 4 um sections prepared from paraffin blocks using KLF factor (4 and 7); this will be done with automated immunostaining using the streptavidin-biotin technique.
  • Interpretation of the stained slides will be done using a semiquantitative score and the results will be statistically analyzed.
  • Sample Size: 30 patients

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age: children, young adolescents younger than 15 years, and young adults (15 to 39 years) Gender: Males and female. Histologically confirmed patients with skeletal or extra-skeletal OS or ES. Both localized and metastatic disease stages.

Exclusion criteria

Patients with second malignant bone sarcoma. Patients with benign bone tumors.

Treatment and study plan

KLF factor (4 and 7)

Diagnostic Test

Immunohistochemical staining of 4 um sections prepared from paraffin blocks using KLF factor (4 and 7) by automated immunostaining using the streptavidin-biotin technique.

Primary outcomes

  1. The prognostic value

    Time frame: 1 year

    Assess the prognostic value of Krüppel-like factors 4 and 7 in bone tumors,

Study contacts

Contact information is provided by the study sponsor or research team.

Fatma S E Ebeid, MD

CONTACT

[email protected]

01095569596

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Official study title

The Prognostic Value of Tissue Expression of Krüppel-Like Factors 4 and 7 in Bone Tumors

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Apr 20, 2025
Registry last updated
Apr 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.